Please login to the form below

Not currently logged in
Email:
Password:

Hollingsworth leaves cancer charity for ABPI

Andrew Hollingsworth appointed policy manager at pharma industry body

Andrew Hollingsworth is to leave the third sector to join industry, moving from Cancer Research UK to the Association of the British Pharmaceutical Industry (ABPI).

Hollingsworth will join the UK pharma trade body on November 25 as policy manager. He leaves his role as public affairs manager at Cancer Research UK.

He will use his experience in the third sector in his new role, which will see him lead the ABPI's work to engage with patient groups. This includes the Patient Organisation Forum, which aims to identify mutual interest and improve collaboration between industry and patient organisations.

Hollingsworth also has industry experience spending more than five years at Novartis a senior manager, public affairs. This followed a period in politics as parliamentary assistant in the European Parliament.

Commenting on his new role, Hollingsworth said: “I am keen to develop the ABPI's engagement with patient organisations in an open, transparent and constructive dialogue."

13th November 2013

From: Research, Sales, Marketing, Regulatory, Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...